GOODWILL AND INTANGIBLE ASSETS (Tables)

6 Months Ended

Jun. 30, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

The following table summarizes the changes in the carrying amount of goodwill:


(in millions)	Amount
Balance at December 31, 2020	$	8,108
Goodwill resulting from the acquisition of MYR	226
Balance at June 30, 2021	$	8,334

Schedule of Finite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:


	June 30, 2021								December 31, 2020
(in millions)	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset - sofosbuvir	$	10,720	$	(5,302)	$	—	$	5,418	$	10,720	$	(4,952)	$	—	$	5,768
Intangible asset - axicabtagene ciloleucel(1)	7,110		(1,298)		—		5,812		6,200		(1,105)		—		5,095
Intangible asset - Trodelvy(2)	5,630		(274)		—		5,356		4,600		(63)		—		4,537
Intangible asset - Hepcludex for HDV	845		(29)		—		816		—		—		—		—
Other	1,410		(592)		1		819		1,377		(540)		(1)		836
Total finite-lived assets	25,715		(7,495)		1		18,221		22,897		(6,660)		(1)		16,236
Indefinite-lived assets - IPR&D(1)(2)(3)	16,120		—		—		16,120		16,890		—		—		16,890
Total intangible assets	$	41,835	$	(7,495)	$	1	$	34,341	$	39,787	$	(6,660)	$	(1)	$	33,126

_______________________________

(1) Gross carrying amount as of June 30, 2021 includes $910 million reclassified from indefinite-lived assets - IPR&D following the March 2021 FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.

(2) Gross carrying amount as of June 30, 2021 includes Trodelvy for metastatic triple-negative breast cancer and Trodelvy for use in adult patients with locally advanced or metastatic urothelial cancer (“UC”), which was granted accelerated approval by FDA in April 2021. The amount related to UC of $1.0 billion was reclassified to finite-lived assets from indefinite-lived assets - IPR&D, following the approval in April 2021.

(3) Gross carrying amount as of June 30, 2021 includes $1.2 billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information.

Schedule of Indefinite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:


	June 30, 2021								December 31, 2020
(in millions)	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset - sofosbuvir	$	10,720	$	(5,302)	$	—	$	5,418	$	10,720	$	(4,952)	$	—	$	5,768
Intangible asset - axicabtagene ciloleucel(1)	7,110		(1,298)		—		5,812		6,200		(1,105)		—		5,095
Intangible asset - Trodelvy(2)	5,630		(274)		—		5,356		4,600		(63)		—		4,537
Intangible asset - Hepcludex for HDV	845		(29)		—		816		—		—		—		—
Other	1,410		(592)		1		819		1,377		(540)		(1)		836
Total finite-lived assets	25,715		(7,495)		1		18,221		22,897		(6,660)		(1)		16,236
Indefinite-lived assets - IPR&D(1)(2)(3)	16,120		—		—		16,120		16,890		—		—		16,890
Total intangible assets	$	41,835	$	(7,495)	$	1	$	34,341	$	39,787	$	(6,660)	$	(1)	$	33,126

_______________________________

(3) Gross carrying amount as of June 30, 2021 includes $1.2 billion recognized from the first quarter 2021 acquisition of MYR. See Note 6. Acquisitions for additional information.

Schedule of Estimated Future Amortization Expense

The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of June 30, 2021:


(in millions)	Amount
2021 (remaining six months)	$	882
2022	1,764
2023	1,764
2024	1,764
2025	1,758
Thereafter	10,289
Total	$	18,221